Includes all of these presentations from this session:

#	Presentation	Speaker
1	Keynote: Can molecularly-based strategies improve esophageal cancer-related outcomes in at-risk populations?	E.T. Hawk (Houston)
2	Access to molecular testing and targeted therapies in France	F. Calvo (NCA, Paris)
3	Which agents are most promising for the clinic now? Selenium, NSAIDs, China-based trials, SCCA	P. Taylor (Bethesda)
4	Which agents are most promising for the clinic now? COXIBs, PPIs, phase 2 trials, Barrett?s/adenoCA	G. Triadafilopoulos (Stanford)
5	Which agents are most promising for the clinic now? Dietary modification	A. Umar (NCI, Bethesda)
6	Which agents are most promising for the clinic now? Statins in the chemoprevention and treatment of esophageal cancer - Data from observational cohort studies	L. Alexandre (Norfolk)
7	Which populations are in need of, or might benefit from, preventive strategies? Barrett?s/adenoCA	Y. Romero (Rochester, MN)
8	How might we identify the most promising targets/agents going forward? Preclinical systems, new targets/agents, preclinical testing	N. Buttar (Rochester, MN)
9	How might we identify the most promising targets/agents going forward? Genomic/epigenomic analyses	A. Umar (NCI, Bethesda)
10	How might we identify the most promising targets/agents going forward? Biomarkers, potential targets in BE/adenoCA	D. Kandioler (Vienna)